Literature DB >> 16572003

Cannabinoid effects on behaviors maintained by ethanol or food: a within-subjects comparison.

Brett C Ginsburg1, Richard J Lamb.   

Abstract

The cannabinoid CB1 antagonist rimonabant (SR141716A) has been proposed as a therapeutic agent for several addictive disorders, including alcoholism. Rimonabant may selectively reduce responding for an ethanol solution compared with an alternative. While this could represent a specific effect of CB1 inhibition on ethanol reinforcement, this could also result from differences in the baseline rates of behavior or experiences between comparison groups. We developed a procedure in rats that allows a within-subject comparison of ethanol and food-maintained responding and provides well matched baseline response rates. We determined the effects of acute doses of rimonabant (0.3-5.6 mg/kg, intraperitoneal) and the CB1 agonist Delta-9-tetrahydrocannabinol (1.0-5.6 mg/kg, intraperitoneal) on responding for food and ethanol under a multiple fixed-ratio schedule. To confirm that rimonabant blocked cannabinoid receptors, the ability of rimonabant to antagonize Delta-9-tetrahydrocannabinol effects in the same subjects under the same reinforcement schedule was also determined. In contrast with previous reports, rimonabant did not significantly alter responding for ethanol or food. The effects of Delta-9-tetrahydrocannabinol on responding for food were completely antagonized by rimonabant, whereas Delta-9-tetrahydrocannabinol effects on responding for ethanol were not. These results suggest that there may be neuroadaptation of the cannabinoid system following aging or chronic self-administration of ethanol.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16572003     DOI: 10.1097/00008877-200605000-00006

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  6 in total

Review 1.  The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.

Authors:  Giancarlo Colombo; Alessandro Orrù; Paola Lai; Claudia Cabras; Paola Maccioni; Marina Rubio; Gian Luigi Gessa; Mauro A M Carai
Journal:  Mol Neurobiol       Date:  2007-07-03       Impact factor: 5.590

2.  Upregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption.

Authors:  Panayotis K Thanos; Vanessa Gopez; Foteini Delis; Michael Michaelides; David K Grandy; Gene-Jack Wang; George Kunos; Nora D Volkow
Journal:  Alcohol Clin Exp Res       Date:  2010-10-19       Impact factor: 3.455

3.  Quantitative mass spectrometry of diabetic kidney tubules identifies GRAP as a novel regulator of TGF-beta signaling.

Authors:  Timothy D Cummins; Michelle T Barati; Susan C Coventry; Sarah A Salyer; Jon B Klein; David W Powell
Journal:  Biochim Biophys Acta       Date:  2009-10-22

4.  Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats.

Authors:  Clare M Mathes; Marco Ferrara; Neil E Rowland
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-04-30       Impact factor: 3.619

5.  Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates.

Authors:  Richard W Foltin; Margaret Haney
Journal:  Pharmacol Biochem Behav       Date:  2007-03-15       Impact factor: 3.533

6.  Drug effects on multiple and concurrent schedules of ethanol- and food-maintained behaviour: context-dependent selectivity.

Authors:  B C Ginsburg; R J Lamb
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.